LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Список акций・Vivani Medical

Vivani Medical

Закрыт

1.21 -3.2

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.21

Макс.

1.23

Ключевые показатели
By Trading Economics
Сотрудники	37

Дивиденды
By Dow Jones
Следующий отчет о доходах	30 мар. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-19M 86M
Предыдущая цена открытия	4.41
Предыдущая цена закрытия	1.21

Vivani Medical График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

27 февр. 2026 г., 23:53 UTC

Популярные акции

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 февр. 2026 г., 22:23 UTC

Приобретения, слияния, поглощения

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 февр. 2026 г., 21:36 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 февр. 2026 г., 15:20 UTC

Отчет

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 февр. 2026 г., 14:43 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 февр. 2026 г., 14:40 UTC

Главные новостные события

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28 февр. 2026 г., 14:38 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 февр. 2026 г., 13:51 UTC

Главные новостные события

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28 февр. 2026 г., 13:47 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 февр. 2026 г., 13:44 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 февр. 2026 г., 13:14 UTC

Отчет

Приобретения, слияния, поглощения

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 февр. 2026 г., 12:41 UTC

Главные новостные события

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28 февр. 2026 г., 02:32 UTC

Отчет

Приобретения, слияния, поглощения

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 февр. 2026 г., 02:00 UTC

Приобретения, слияния, поглощения

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 февр. 2026 г., 02:00 UTC

Приобретения, слияния, поглощения

Six Months, 9 Offers and $81 Billion. How -2-

28 февр. 2026 г., 00:01 UTC

Приобретения, слияния, поглощения

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 февр. 2026 г., 23:46 UTC

Приобретения, слияния, поглощения

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 февр. 2026 г., 23:33 UTC

Приобретения, слияния, поглощения

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

27 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

27 февр. 2026 г., 21:30 UTC

Отчет

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 февр. 2026 г., 21:30 UTC

Обсуждения рынка

Приобретения, слияния, поглощения

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 февр. 2026 г., 21:20 UTC

Приобретения, слияния, поглощения

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 февр. 2026 г., 21:17 UTC

Отчет

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 февр. 2026 г., 21:10 UTC

Приобретения, слияния, поглощения

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 февр. 2026 г., 21:09 UTC

Приобретения, слияния, поглощения

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 февр. 2026 г., 21:00 UTC

Отчет

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 февр. 2026 г., 20:31 UTC

Приобретения, слияния, поглощения

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 февр. 2026 г., 20:24 UTC

Обсуждения рынка

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 февр. 2026 г., 20:23 UTC

Обсуждения рынка

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

Сравнение c конкурентами

Изменение цены

Vivani Medical Прогноз

Консенсус по рейтингу

By TipRanks

0 ratings

Покупка

Удержание

Продажа

Основано на мнении 0 аналитиков, присваивавших рейтинги акциям Vivani Medical – Данные за последние 3 месяца.

Финансовые показатели

О компании Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.